Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

Completed · Not applicable

Conditions studied: Liver Cirrhosis, Coagulopathy

In brief

The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood products in preventing bleeding after teeth extraction in persons with severe liver disease being evaluated for liver transplant.

Key facts

Study ID

NCT00816127

Run by

Icahn School of Medicine at Mount Sinai

People needed

36

Starts

2003-10-01

Expected to finish

2007-05-01

Last updated by the study team

2009-01-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult patients with biopsy-proven liver cirrhosis or clinical/radiological evidence of cirrhosis, requiring dental extraction
• platelet count of 30,000-50,000/microL and/or INR 2.0-3.0

You may not qualify if…

• the presence of other bleeding disorders besides cirrhosis such as renal dysfunction (creatinine > 2.0) or HIV
• receipt of blood transfusion within 2 weeks prior to study
• recent acute decompensation of liver cirrhosis
• malignancy excluding hepatocellular carcinoma in the absence of portal vein thrombosis
• treatment with anti-platelet medications (aspirin, non-steroidal anti-inflammatory drugs or clopidogrel) within ten days prior to the extraction
• documented allergy to DDAVP.

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.